Table 3.
Disease Modifying Anti-Rheumatic Drugs Used by Patient (Not per Visit)
| NP or PA | Rheumatologist only | p-values | |
|---|---|---|---|
| Patients | 158 | 143 | |
|
| |||
| Synthetic DMARDs, any | 135 (85.4%) | 105 (73.4%) | 0.01 |
|
| |||
| Methotrexate | 105 (66.5%) | 73 (51.1%) | |
| Hydroxychloroquine | 40 (25.3%) | 35 (24.5%) | |
| Sulfasalazine | 6 (3.8%) | 5 (3.5%) | |
| Leflunomide | 29 (18.4%) | 20 (13.9%) | |
| Gold salts | 1 (0.6%) | 0 (0.0%) | |
| Auranofin | 1 (0.6%) | 1 (0.7%) | |
| Azathioprine | 1 (0.6%) | 5 (3.5%) | |
|
| |||
| Biologic DMARDs, any | 126 (79.8%) | 67 (46.9%) | <.0001 |
|
| |||
| Infliximab | 45 (28.5%) | 20 (14.0%) | |
| Etanercept | 28 (17.7%) | 27 (18.9%) | |
| Adalimumab | 30 (19.0%) | 13 (9.1%) | |
| Abatacept | 26 (16.5%) | 5 (3.5%) | |
| Tocilizumab | 15 (9.5%) | 6 (4.2%) | |
| Rituximab | 7 (4.4%) | 8 (5.6%) | |
| Golimumab | 11 (7.0%) | 2 (1.4%) | |
| Certolizumab pegol | 6 (3.8%) | 0 (0.0%) | |
| Tofacitinib | 0 (0.0%) | 4 (2.8%) | |
| Anakinra | 1 (0.6%) | 0 (0.0%) | |
NP, nurse practitioner; PA, physician assistant; DMARD, disease-modifying anti-rheumatic drug.